Get the Stockscreener App
2.49
0.80%
-0.02
After Hours:
2.49
Avenue Therapeutics Inc stock is traded at $2.49, with a volume of 18,795.
It is down -0.80% in the last 24 hours and down -1.97% over the past month.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
See More
Previous Close:
$2.51
Open:
$2.5
24h Volume:
18,795
Relative Volume:
0.43
Market Cap:
$3.56M
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.4975
EPS:
-5.0046
Net Cash Flow:
$-12.45M
1W Performance:
+4.18%
1M Performance:
-1.97%
6M Performance:
-77.49%
1Y Performance:
-95.30%
1-Day Range:
$2.46
$2.55
1-Week Range:
$2.21
$2.59
52-Week Range:
$2.21
$53.53
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Avenue Therapeutics Inc Stock (ATXI) Latest News
Avenue Therapeutics grants stock units to top executives By Investing.com - Investing.com Canada
Avenue Therapeutics grants stock units to top executives - Investing.com
Avenue Therapeutics Incentive Plan Awards Key Executives - TipRanks
Week Ahead (Apr.12- Apr.16): PDUFA Dates, Data Readouts (RCUS, ATXI, MRTX, KDNY…) - RTTNews
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Avenue Therapeutics stock hits 52-week low at $2.23 By Investing.com - Investing.com Canada
Avenue Therapeutics stock hits 52-week low at $2.23 - Investing.com
Avenue Supermart shares rise 1.49% as Sensex climbs - The Economic Times
Avenue Supermart rises 1.49% as Sensex climbs - The Economic Times
Share price of Avenue Supermart falls as Sensex gains 251.05 points - The Economic Times
Victory Capital Management Inc. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Forest Avenue Capital Management LP Has $44.92 Million Position in Walmart Inc. (NYSE:WMT) - Defense World
Postoperative acute pain Market Size is Set for Rapid Growth as - openPR
Forest Avenue Capital Management LP Has $24.54 Million Holdings in GE Vernova Inc. (NYSE:GEV) - Defense World
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Amplia Therapeutics’ Drug Fast-Tracked by FDA - TipRanks
First Avenue IPO on Nomu 740% oversubscribed; offer price set at SAR 6 - بوابة أرقام المالية
Avenue Supermart shares down 0.27% as Nifty gains - The Economic Times
Avenue Supermart shares fall 0.27 per cent in Thursday's trading session - The Economic Times
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - AccessWire
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - StockTitan
Avenue Supermart shares up 0.35% as Nifty gains - The Economic Times
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
2 Dead In Series Of Police Shootouts That Shut Down Victory Boulevard - Patch
Meet Microsoft’s new COO—a former superstar CFO from GE - Fortune
Share price of Avenue Supermart rises as Nifty strengthens - The Economic Times
Allarity Therapeutics appoints new CFO - Investing.com India
Allarity Therapeutics expands ATM agreement, appoints new CFO - Investing.com
Allarity Therapeutics appoints new CFO By Investing.com - Investing.com Australia
Allarity Therapeutics Names Alex Epshinsky Finance Chief - MarketWatch
Allarity Therapeutics appoints new CFO - Investing.com
Allarity appoints Alex Epshinsky as CFO - TipRanks
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nasdaq
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Avenue Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Avenue Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Avenue Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time - Quantisnow
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - BioSpace
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - StockTitan
United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Park Avenue Securities LLC - Defense World
Park Avenue Securities LLC Sells 1,290 Shares of Expeditors International of Washington, Inc. (NASDAQ:EXPD) - Defense World
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - StockTitan
Kymera Therapeutics (NASDAQ:KYMR) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPS - Defense World
Park Avenue Securities LLC Has $1.11 Million Stock Holdings in Voya Financial, Inc. (NYSE:VOYA) - Defense World
Voyager Therapeutics (NASDAQ:VYGR) Releases Quarterly Earnings Results, Beats Expectations By $0.20 EPS - Defense World
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):